Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world Study on Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer (NSCLC)

NCT04206787 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT04206787
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04206787 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world Study on Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer (NSCLC)
Lead sponsor
Boehringer Ingelheim
Phase
Observational
Overall status
Completed
Start date
May 20, 2020
Completion date
December 22, 2023
Enrollment
72 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous, non-small cell lung cancer